Lu-DOTATATE PRRT dosimetry:
|
|
- Luke Fields
- 6 years ago
- Views:
Transcription
1 177 Lu-DOTATATE PRRT dosimetry: From theory to practice Silvano Gnesin Medical Physics department Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland Gwennaëlle Marin Medical Physics and Nuclear Medicine departments Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Bruxelles, Belgique
2 Theranostics = Therapeutic + Diagnostic Use of the same pharmaceutic labeled with different radionuclides to be used alternatively as diagnostic and therapeutic agent Expl: Use of the same pharmaceutic labeled with one radionuclide to be used simultaneously as diagnostic and therapeutic agent We treat what we see; we see what we treat We have to Know our target Chose the agent Chose the weapon and the bullet Ga-68/Lu-177 Lu-177 only CHELATOR PEPTIDE sstr
3 Theranostics: weapon CHELATOR PEPTIDE sstr 68 Ga-DOTATATE = 68 Gallium-DOTA-(Tyr3)-octreotate 68 Gallium = β + emitter DOTA = chelator (Tyr 3 )-octreotate = peptide = synthetic somatostatine analogue Neuroendocrine tumors with over-expressed somatostatine receptors (sstr) 68 Ga β + emitter => PET imaging Receptor imaging Staging/selection of patients Quantification Therapy response prediction (?)
4 Theranostics: weapon CHELATOR PEPTIDE sstr 177 Lu-DOTATATE = 177 Lu-DOTA-(Tyr3)-octreotate 177 Lutetium = β and γ emitter DOTA = chelator (Tyr 3 )-octreotate = peptide = synthetic somatostatine analogue Neuroendocrine tumors with over-expressed somatostatine receptors (sstr) 177 Lu β - emitter => therapy (MRT) γ emitter => SPECT imaging Receptor imaging Quantification Dosimetry β kev max γ 208 kev
5 Why dosimetry? Chemotherapy wait Nuclear medicine Other solution pre-therapeutic 68 Ga-DOTATATE PET/CT A small activity of Compute absorbed dose 177 Lu-DOTATATE SPECT/CT at 24h PI
6 Why dosimetry? 177 Lu-DOTATATE SPECT/CT at 24h PI 177 Lu-DOTATATE SPECT/CT at 24h PI Treatment cycle 1 Treatment cycle 1 Patient profiles are similar (to the best of our knowledge): Female Intestinal (ileal) neoplasia Similar Ki67
7 Why dosimetry? 177 Lu-DOTATATE SPECT/CT at 24h PI 177 Lu-DOTATATE SPECT/CT at 24h PI Treatment cycle 1 Treatment cycle 4 Treatment cycle 1 Treatment cycle 4 Patient profiles are similar (to the best of our knowledge): Female Intestinal (ileal) neoplasia Similar Ki67 Different responses When do we stop the therapy?
8 Why dosimetry? Maximum dose limit of 23 Gy to kidneys is derived from EBRT and PRRT with 90 Y-DOTATOC 5% probability of severe kidney toxicity within 5 years Differences between molecular (MRT) and external beam radiation therapy (EBRT): -Dose rate -Fractionation Possible different biological effect -Heterogeneity of energy/dose deposition -citotoxic mechanisms EBRT dose causing 5% renal toxicity after 5 y = 23 Gy delivered by fractions of 2Gy d = 2 Gy/fraction nd = 23 Gy T1 = 0h eff 2 α/β = 2.6 Gy for kidneys T1 = 2.8 h for kidneys rep 2 = 40.7 Gy MRT Limit BED = 40 Gy Barone R. et al. J Nucl Med. 2005
9 Why dosimetry? EBRT dose causing 5% renal toxicity after 5 y = 23 Gy delivered by fractions of 2Gy d = 2 Gy/fraction nd = 23 Gy T1 = 0h eff 2 α/β = 2.6 Gy for kidneys T1 = 2.8 h for kidneys rep 2 = 40.7 Gy MRT Limit BED = 40 Gy BED as function of absorbed dose for healthy kidneys after PRRT with 90 Y- and 177 Lu-labeled compounds. Dotted lines denote intersection of BED of 40 Gy and corresponding cycle- and nuclide-dependent absorbed kidney doses. Vertical light blue solid line denotes normally accepted tolerable absorbed dose (23 Gy) for healthy kidneys. U. Eberlein et al., J. Nuc. Med. 58, 2017
10 Why dosimetry? Predictability of the dosimetry based on the fist therapy cycle Garkavij et al., Cancer 2010
11 Why dosimetry? N of cycles to reach a given absorbed dose to kidneys is patient specific If no risk factors Optimization by individualized dosimetry Maximize tumor dose (efficacy) Control to organ at risk (safety) n cycles >4 for 78% of patients A cycle = 7.4 GBq Data from hybrid planar+spect kidney dosimetry A. Sundlöv et al. EJNMMI 2017
12 A (Bq) How to perform dosimetry? In theory, in general: D r T = E(r T) m r T In theory, in nuclear medicine: D r T = A(r S ) S(r T r S ) r S r S1 r S2 = A(r S ) i r S Y ie i Φ(r T r S,E i ) m(r T ) metrology r T In practice, in nuclear medicine: Φ(r T r S, E i ) : Olinda? Voxel based? m r T : which modality? A(r S ) : which time-points? how to quantify activity? which interpolation/pharmacokinetic? A r S = A t 0 = TIAC t (hour) Bolch et al., JNM 2009
13 Standard dosimetry procedure Drug preparation and administration Source/target organ definition Data acquisition (Which data? When?) Activity quantification on each acquired data TAC (Time Activity Curve) computation TIAC (Time-Integrated Activity Coefficient) computation Computation of absorbed dose to organs-at-risk
14 Drug administration Standard 4-cyles, 7.4 GBq Cycle Cumulated activity safe for most of patients Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. D.J. Kwekeboom, et al. J Clin Oncol 2005 Apr 20;23(12): Compared to EBRT, low dose-rate PRRT potentially enable higher dose before severe toxicity appears Patient without risk factor (hypertension, diabetes) could receive up to BED = 40Gy without severe renal toxicity Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors L. Bodei et al. Eur J Nucl Med Mol Imaging (2008) 35: Ongoing study in Lund confirms the BED=40Gy in patient without risk factor is safe Individualized 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry A. Sundlöv et al. Eur J Nucl Med Mol Imaging (2017) 44: )
15 Drug administration 177 Lu-DOTATATE should be administered by trained medical staff with supporting nursing staff with a medical physics expert available Reduced kidney dose (10-60%) is obtained by amino acid co-administration for somatostatine receptor agonist radiolabeled with 90 Y Matters to debate in 177 Lu PRRT (common practice in many centers)
16 Our experience Standard therapy scheme: 4 cycles of 7,4 GBq of 177 Lu-DOTATATE 4 years Institut Jules Bordet experience with 177 Lu-DOTATATE therapy 63 patients (26 part of LuMen) 186 therapy cycles (80 part of LuMen) The whole procedure is identical for all patients (routine & LuMen) LuMen: Prospective phase II clinical study «177 Lu-octreotate treatment outcome prediction using multimodality imaging in refractory neuroendocrine tumours»
17 Drug administration Antiemetics 1 hour before 177 Lu-DOTATATE injection Amino acids from 0,5 h before to 4 h after injection Manual intravenous 177 Lu-DOTATATE injection lasts from 10 to 20 minutes Patient s weight and size Prepared activity + measurement hour Remaining activity + measurement hour Start and end of injection => net injected activity (MBq) Standard acquisition protocol + hours
18 Standard dosimetry procedure Drug preparation and administration Source/target organ definition Data acquisition (Which data? When?) Activity quantification on each acquired data TAC (Time Activity Curve) computation TIAC (Time-Integrated Activity Coefficient) computation Computation of absorbed dose to organs-at-risk
19 Source/target organ definition D r T = A(r S ) S(r T r S ) r S = A(r S ) i r S Y ie i Φ(r T r S,E i ) m(r T ) r S1 r S2 r T For MRT with 177 Lu-DOTATATE: Source organs: Kidneys Red marrow Liver Spleen Remainder of the body => Cumulated activity Target organs or organs-at-risk: Kidneys Red marrow => Absorbed dose Bolch et al., JNM 2009
20 Standard dosimetry procedure Drug preparation and administration Source/target organ definition Data acquisition (Which data? When?) Activity quantification on each acquired data TAC (Time Activity Curve) computation TIAC (Time-Integrated Activity Coefficient) computation Computation of absorbed dose to organs-at-risk
21 Data acquisition Each injection is preceded by 18 FDG PET/CT, 68 Ga-DOTATATE PET/CT and MRI Each injection is followed by 3 SPECT/CT (4, 24, 168 h PI) and 5 blood samples (0.5, 1, 4, 24, 168 h PI) Previous month 18 FDG PET/CT 68 Ga-DOTATATE PET/CT MRI or CT Blood Blood SPECT/CT Blood SPECT/CT Blood SPECT/CT 177 Lu-DOTATATE injection Patient leaves hospital Siegel et al., JNM 1999; Guerriero et al., Biomed Res Int 2013
22 Data acquisition M: Planar imaging M2: Hybrid planar + SPECT M3: only SPECT acq. Fully planar dosimetry tends to overestimate kidney dose exposure compared to SPECT-based methods (overlapping activity with surrounding tissues) Garkavij et al., Cancer 2010
23 Standard dosimetry procedure Drug preparation and administration Source/target organ definition Data acquisition (Which data? When?) Activity quantification on each acquired data TAC (Time Activity Curve) computation TIAC (Time-Integrated Activity Coefficient) computation Computation of absorbed dose to organs-at-risk
24 Activity quantification Activity = volume X specific activity Organ volumes on first SPECT/CT: CT contours for spleen, kidneys and liver Body weight for remainder of the body OLINDA volumes balance for patient size for red marrow Brindle et al., Cancer Biother Radiopharm 2006 Organ specific activities on each SPECT/CT and blood sample: 3 spheres for spleen, kidneys and remainder of the body Gross liver activity contour (liver + hepatic lesion) red marrow = blood (no specific uptake) Spheres in spleen and kidney Gross liver contour ROI in remainder of the body Blood activity measurement Sandström et al., EJNMMI 2015; Forrer et al., EJNMMI 2009
25 Standard dosimetry procedure Drug preparation and administration Source/target organ definition Data acquisition (Which data? When?) Activity quantification on each acquired data TAC (Time Activity Curve) computation TIAC (Time-Integrated Activity Coefficient) computation Computation of absorbed dose to organs-at-risk
26 TAC computation SPECT 4h SPECT 24h SPECT 168h Kletting et al., Med Phys 2013; Guerriero et al., Biomed Res Int 2013
27 TAC computation Blood 0.5 & 1h Blood 4h Blood 24h Blood 168h Kletting et al., Med Phys 2013; Guerriero et al., Biomed Res Int 2013
28 Standard dosimetry procedure Drug preparation and administration Source/target organ definition Data acquisition (Which data? When?) Activity quantification on each acquired data TAC (Time Activity Curve) computation TIAC (Time-Integrated Activity Coefficient) computation Computation of absorbed dose to organs-at-risk
29 TIAC computation A (Bq) Time-integrated activity coefficients (TIAC) computation for source organs T eff_early T eff_late A r S = A t 0 = TIAC t (hour) TIAC T eff_early T eff_late Mass
30 Standard dosimetry procedure Drug preparation and administration Source/target organ definition Data acquisition (Which data? When?) Activity quantification on each acquired data TAC (Time Activity Curve) computation TIAC (Time-Integrated Activity Coefficient) computation Computation of absorbed dose to target organs
31 Absorbed dose computation Source organs TIAC Effective half-life Mass r S1 r S2 r T OLINDA/EXM software Patient specific organ mass Stabin et al., JNM 2005; Divoli et al., JNM 2009 Organ Doses (msv/7,64 GBq) Target Organs Beta Photon Total Adrenals 1,77E002 6,63E001 2,43E002 Brain 1,77E002 1,49E001 1,92E002 Breasts 1,77E002 1,46E001 1,91E002 Gallbladder Wall 1,77E002 5,67E001 2,34E002 LLI Wall 1,77E002 2,60E001 2,03E002 Small Intestine 1,77E002 3,31E001 2,10E002 Stomach Wall 1,77E002 4,18E001 2,19E002 ULI Wall 1,77E002 3,58E001 2,13E002 Heart Wall 1,77E002 3,19E001 2,09E002 Kidneys 8,69E003 1,86E002 8,87E003 Liver 1,52E003 8,07E001 1,60E003 Lungs 1,77E002 2,91E001 2,06E002 Muscle 1,77E002 2,25E001 1,99E002 Ovaries 1,77E002 2,77E001 2,05E002 Pancreas 1,77E002 6,65E001 2,43E002 Red Marrow 2,57E002 2,63E001 2,84E002 Osteogenic Cells 6,87E002 4,22E001 7,29E002 Skin 1,77E002 1,20E001 1,89E002 Spleen 1,17E004 2,38E002 1,19E004 Thymus 1,77E002 2,12E001 1,98E002 Thyroid 1,77E002 1,59E001 1,93E002 Urinary Bladder Wall 1,77E002 2,34E001 2,00E002 Uterus 1,77E002 2,64E001 2,03E002 Total Body 2,68E002 2,48E001 2,93E002
32 Lesion dosimetry Lesion mass definition on 68 Ga-DOTATATE PET/CT Threshold = mean SUV in inferior left kidney cortex Lesion activity quantification on 177 Lu-DOTATATE SPECT/CT Region growing from hottest voxel until reaching defined mass 4 h PI 24 h PI 168 h PI 177 Lu-DOTATATE SPECT TAC computation Measured activities are fitted with a bi-exponential function A measured /A injected Time after injection (h)
33 Lesion dosimetry RC (A measured /A expected ) TAC corrected for partial volume effect Phantom-based PVE correction for spheres Sphere volume (cm³) Buvat et al., JNM 2007
34 Dose (mgy/mbq) RC (A measured /A expected ) Dose rate (mgy/h/gbq) Lesion dosimetry Lesion TAC A measured /A injected Time after injection (h) Lesion time-dose rate curves Phantom-based PVE correction for spheres Sphere volume (cm³) Time after injection (h) 1.E+04 OLINDA sphere model for 177 Lu 1.E+03 1.E+02 1.E+01 1.E+00 1.E-01 1.E sphere mass (g)
35 Dosimetry results for organs-at-risk High inter-patient variability High inter-study variability Kidneys Red marrow Author Number of patients d [Gy/GBq] Del Prete et al. EJNMMI ± 0.2 Sandström et al. JNM [0.47; 0.61; 0.73] Svensson et al. EJNMMI Phys ± 0.2 Our results 47 [0.61; 0.77; 0.98] Wehrmann et al. Cancer Biother Radiophar ± 0.3 Garkavij et al. Cancer ± 0.3 Sandström et al. JNM [0.012; 0.016; 0.022] Svensson et al. EJNMMI Phys ± Our results 47 [0.023; 0.028; 0.032] Forrer et al. EJNMMI ± Del Prete et al. EJNMMI ± Wehrmann et al. Cancer Biother Radiophar ± 0.02 Bergsma et al. EJNMMI ± 0.007
36 A (Bq) Dosimetry results for organs-at-risk Reduced intra-patient (inter-cycle) variability: Normalized mean = 1 (N=27) nv SD (%) nt 1/2eff SD (%) ntiac SD (%) left kidney organ at risk right kidney red marrow liver source organ spleen remainder T eff_early T eff_late A r S = A t 0 = TIAC t (hour)
37 Dosimetry results for lesions 2.7 mgy/mbq 5.4 mgy/mbq 8.1 mgy/mbq 10.8 mgy/mbq 21.6 mgy/mbq lesions Author Number of patients d [Gy/GBq] Gupta et al. Clin Nucl Med ± 0.68 Garkavij et al. Cancer [0.1; 6.7; 20] Ilan et al. JNM [1.4; 6.7; 22.9] Wehrmann et al. Cancer Biother Radiophar ± 11.1 Ilan et al., JNM 2015 Tumor dose response relationship for patients with PNETs treated with PRRT using 177 Lu-DOTATATE, including tumors larger than 2.2 cm (A) and only tumors larger than 4 cm (B) Eberlein et al., JNM 2017
38 Conclusion Important inter-patient variability => need for dosimetry to individualize therapy, improve patient safety and therapeutic efficacy BUT No standard dosimetry methodology proposed yet => variability of dosimetry results in different studies To improve dosimetry use and reliability, standardization, precision and accuracy are key points!
Dosimetry and radiobiology for Peptide Receptor Radionuclide Therapy
Dosimetry and radiobiology for Peptide Receptor Radionuclide Therapy Short-ranged particle emitters for targeted radionuclide therapy require specific dosimetry and radiobiology Mark Konijnenberg Melodi
More informationTheranostics in Nuclear Medicine
Theranostics in Nuclear Medicine Patrick FLAMEN, MD, PhD Head Nuclear Medicine Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) n Theranostics in Nuclear Medicine n A form of (nuclear) diagnostic
More informationDosimetry in Targeted Radionuclide Therapy: The Bad Berka Dose Protocol Practical Experience
10.5005/jp-journals-10028-1058 REVIEW ARTICLE Dosimetry in Targeted Radionuclide Therapy: The Bad Berka Dose Protocol Practical Experience Christiane Schuchardt, Harshad Kulkarni, Carolin Zachert, Richard
More informationQuantitative Theranostics in Nuclear Medicine
Quantitative Theranostics in Nuclear Medicine M. Lassmann Klinik und Poliklinik für Nuklearmedizin Direktor: Prof. Dr. A. Buck Contents What is Theranostics? Potential Targets Basic Principles of Quantitative
More informationAustin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate)
Austin Radiological Association Ga-68 NETSPOT (Ga-68 dotatate) Overview Ga-68 dotatate binds to somatostatin receptors, with highest affinity for subtype 2 receptors (sstr2). It binds to cells that express
More informationIART and EBRT, an innovative approach
External beam radiotherapy and nuclear medicine therapy: which kind of integration? Mahila Ferrari mahila.ferrari ferrari@ieo.it A different NM and RT integration... Radionuclide therapy combined to EBRT
More informationPhysical Bases : Which Isotopes?
Physical Bases : Which Isotopes? S. Gnesin Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland 1/53 Theranostic Bruxelles, 2 Octobrer 2017 Theranostic : use of diagnostic
More informationErasmus Experience. Lu-DOTA-octreotate PRRT
Erasmus Experience 177 Lu-DOTA-octreotate PRRT Mark Konijnenberg Erasmus MC, Rotterdam, Netherlands METRO/MRT meeting 2015, NPL, Teddington Leading questions? 1. For which MRT procedure dosimetry is used?
More informationJoint ICTP-IAEA Advanced School on Internal Dosimetry. Trieste, April 2010
Joint ICTP-IAEA Advanced School on Internal Dosimetry Trieste, 12-16 April 2010 Dosimetry in PRRT: what for Dosimetry has the purpose to address %&!"# '!&!"#!(%)* $ *!$+ Most Used Radiopeptides for PRRT
More informationPrecision of pre-sirt predictive dosimetry
International Course on THERANOSTICS AND MOLECULAR RADIOTHERAPY Precision of pre-sirt predictive dosimetry Hugo Levillain Department of Nuclear Medicine Medical Physics Jules Bordet Institute, Université
More informationWhole-body biodistribution and radiation dosimetry estimates for the β-amyloid radioligand [ 11 C]MeS-IMPY in non-human primates
Whole-body biodistribution and radiation dosimetry estimates for the β-amyloid radioligand [ 11 C]MeS-IMPY in non-human primates Molecular Imaging Branch, NIMH Bldg. 1 Rm. B3-10 September 6 th, 2006 The
More informationUse Of MCNP With Voxel-Based Image Data For Internal Dosimetry Applications
Use Of MCNP With Voxel-Based Image Data For Internal Dosimetry Applications The Monte Carlo Method: Versatility Unbounded In A Dynamic Computing World Chattanooga, TN, USA, April 17-21, 2005 M. G. Stabin
More informationIndividualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)
Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy) FMU/ICRP workshop 2017 Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK ICRP Task Group 101
More informationPeptide Receptor Radionuclide Therapy using 177 Lu octreotate
Peptide Receptor Radionuclide Therapy using 177 Lu octreotate BLR Kam, Erasmus Medical Centre, Rotterdam DJ Kwekkeboom, Erasmus Medical Centre, Rotterdam Legal aspects As 177 Lu-[DOTA 0 -Tyr 3 ]octreotate
More informationIn Vivo Measurement and Characterization of a Novel Formulation of [ 177 Lu]-DOTA-Octreotate
In Vivo Measurement and Characterization of a Novel Formulation of [ 177 Lu]-DOTA-Octreotate Dale L Bailey 1,*, Thomas M Hennessy 2, Kathy P Willowson 3, E Courtney Henry 3, David LH Chan 1, Alireza Aslani
More informationEN TERAPIA METAByLICA NO ESTrNDAR CON 177 Lu, 90 Y y 223 Ra
Jornada científica RADIOFuSICA DE LA DOSIMETRuA INTERNA EN LOS PROCEDIMIENTOS TERAPÉUTICOS CON RADIOFrRMACOS DOSIMETRIA FuSICA Y CLuNICA EN TERAPIA METAByLICA NO ESTrNDAR CON 177 Lu, 90 Y y 223 Ra Pablo
More informationRenal function affects absorbed dose to the kidneys and haematological toxicity during 177 Lu-DOTATATE treatment
Eur J Nucl Med Mol Imaging (2015) 42:947 955 DOI 10.1007/s00259-015-3001-1 ORIGINAL ARTICLE Renal function affects absorbed dose to the kidneys and haematological toxicity during 177 Lu-DOTATATE treatment
More informationTheragnostics for bone metastases. Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK
Theragnostics for bone metastases Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK NPL 2015 Ra-223 Biodistribution & dosimetry Ra-223: 11.4 days half-life, range of 100 µm Six
More informationMEDICAL POLICY EFFECTIVE DATE: 06/21/07 REVISED DATE: 05/14/08, 04/16/09, 03/18/10, 03/17/11, 03/15/12, 02/21/13, 02/20/14, 02/19/15
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationPeptide Receptor Radionuclide Therapy (PRRT) of NET
Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None
More informationInternational Radiation Protection Association 12 th International Congress Buenos Aires, Argentina October 19-24, Seminar I
International Radiation Protection Association 12 th International Congress Buenos Aires, Argentina October 19-24, 2008 Seminar I IRPA 12 Radiological Protection of Patient in Nuclear Medicine Ana María
More informationAmira K. Brown, Ph.D. Molecular Imaging Branch, NIMH Bldg. 1 Rm. B3-10
Whole-body biodistribution and radiation dosimetry estimates for the metabotropic glutamate receptor subtype 5 (mglur5) radioligand [ 18 F]SP203 in nonhuman primates Amira K. Brown, Ph.D. Molecular Imaging
More informationStandardization of Radiopharmaceutical Dosimetry
Standardization of Radiopharmaceutical Dosimetry Jonathon A. Nye, PhD Department of Radiology and Imaging Sciences Emory University SEAAPM 2011 Myrtle Beach, SC Review of Dosimetry Nomenclature Dose Gray
More informationTreatment failure in cancer is often attributed to insufficient
Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing Lu-DOTA-Octreotate Treatment Mattias Sandström 1,2, Ulrike Garske-Román 2,3, Dan Granberg 3, Silvia Johansson 2, Charles Widström
More informationThe Management of Imaging Procedure Dose Nuclear Medicine Dose Indices
The Management of Imaging Procedure Dose Nuclear Medicine Dose Indices Wesley E. Bolch, PhD, PE, DABHP, FHPS, FAAPM Director, Advanced Laboratory for Radiation Dosimetry Studies Department of Biomedical
More informationCalculation methods in Hermes Medical Solutions dosimetry software
Calculation methods in Hermes Medical Solutions dosimetry software Helena McMeekin MSc. Clinical Applications Scientist, Hermes Medical Solutions MRTDosimetry Scientific Workshop The Principals and Clinical
More informationDosimetry (Dose Estimation) of Internal Emitters. Outline. For Radiation Effects, is Dose the only Answer? Estimation of Dose and not Dosimetry
Dosimetry (Dose Estimation) of Internal Emitters. Lawrence E. Williams, PhD City of Hope National Medical Center Duarte CA 91010 lwilliams@coh.org Outline 1. Dose Estimation Formula D = S*Ã 2. Determination
More informationMEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)
MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including an Essential
More informationPRRT in Management of NETs. Ioannis Karfis, MD PhD Assistant Head of Clinic Nuclear Medicine Dept IJB, Brussels
PRRT in Management of NETs Ioannis Karfis, MD PhD Assistant Head of Clinic Nuclear Medicine Dept IJB, Brussels THERAPEUTIC TARGETS in NENs Pavel M: Neuroendocrinology 2013;97:99-112 THERAPEUTIC ARENA in
More informationSomatostatin receptor agonists and antagonists Melpomeni Fani
Somatostatin receptor agonists and antagonists Melpomeni Fani Clinic of Radiology and Nuclear Medicine University of Basel Hospital, Switzerland Somatostatin and somatostatin receptors Human Somatostatin
More informationNeuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear
More informationSIRT in Neuroendocrine Tumors
SIRT in Neuroendocrine Tumors Marnix G.E.H. Lam, MD PhD Professor of Nuclear Medicine AVL Amsterdam UMC Utrecht ENETS Center of Excellence, The Netherlands Disclosure of speaker s interests Consultant
More informationMONTE CARLO BASED SPECT ACTIVITY QUANTIFICATION AND TUMOR DOSIMETRY FOR 177 LU-DOTATATE TREATMENTS
SAHLGRENSKA ACADEMY MONTE CARLO BASED SPECT ACTIVITY QUANTIFICATION AND TUMOR DOSIMETRY FOR 177 LU-DOTATATE TREATMENTS Ida Marin Essay/Thesis: Program and/or course: Level: Semester/year: Supervisors:
More informationRadiolabeled somatostatin analogs such as 111 In-DTPAoctreotide
Radiation Dose Distribution in Human Kidneys by Octreotides in Peptide Receptor Radionuclide Therapy Mark Konijnenberg 1, Marleen Melis 2, Roelf Valkema 2, Eric Krenning 2, and Marion de Jong 2 1 Research
More informationSARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY
SEEING IS BELIEVING SARCOPHAGINE CHELATORS AND COPPER ISOTOPES FOR IMAGING AND THERAPY Sydney Vital and STEaM Neuroendocrine Tumour Preceptorship May 2018 Amos Hedt Head of Clinical Development 1 CLARITY
More informationDosimetry in Nuclear Medicine Therapies
Dosimetry in uclear Therapies F. Forrer Institut of uclear University ospital Basel uclear Therapies Radioiodine Phosphonates Metabolites (e.g. 131 I-mIBG) Radiopeptides Radioimmunotherapy Radiosynoviothesis
More informationMETROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY. Glenn Flux
METROLOGY TO SUPPORT INNOVATION IN MOLECULAR RADIOTHERAPY Glenn Flux Head of Radioisotope Physics Royal Marsden Hospital & Institute of Cancer Research Sutton UK CGPM 2018 glenn.flux@icr.ac.uk Overview
More informationMEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)
MEDICAL POLICY SUBJECT: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) POLICY NUMBER: 7.01.78 CATEGORY: Technology Assessment EFFECTIVE DATE: 06/21/07 REVISED DATE: 05/14/08, 04/16/09, 03/18/10, 03/17/11,
More informationFacilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017
Facilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017 CANM ANNUAL SCIENTIFIC MEETING APRIL 20-23, 2017 TORONTO, ONTARIO I do not have a financial interest, arrangement or affiliation
More informationA Real-Time Monte Carlo System for Internal Dose Evaluation Using an Anthropomorphic Phantom with Different Shapes of Tumors Inserted
A Real-Time Monte Carlo System for Internal Dose Evaluation Using an Anthropomorphic Phantom with Different Shapes of Tumors Inserted J. Wu, S. J. Chang, B. J. Chang, I. J. Chen, J. H. Chiu Health Physics
More informationNet Cancer Day Webinar
Net Cancer Day Webinar The webinar will start shortly Please make sure to dial in using the numbers provided or in the upper right hand side of the screen select Switch to Interactive Meeting to enable
More informationAustin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF)
Austin Radiological Association Nuclear Medicine Procedure PET SODIUM FLUORIDE BONE SCAN (F-18 NaF) Overview Indication Sodium Fluoride F18 injection is a radioactive diagnostic agent for positron emission
More informationClinical Implementation of patient-specific dosimetry, comparison with absorbed fraction-based method
Clinical Implementation of patient-specific dosimetry, comparison with absorbed fraction-based method George Sgouros, Ph.D. Russell H. Morgan Dept of Radiology & Radiological Science Johns Hopkins University,
More informationCase Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT
Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationApplication of 3D Printing to Molecular Radiotherapy Phantoms. Nick Calvert Nuclear Medicine Group The Christie NHS Foundation Trust, Manchester
Application of 3D Printing to Molecular Radiotherapy Phantoms Nick Calvert Nuclear Medicine Group The Christie NHS Foundation Trust, Manchester Molecular Radiotherapy Radionuclide administered to patient
More informationFMU-ICRP Workshop on Radiological Protection in Medicine Current Status in Radionuclide Therapy Tuesday, October 3, 2017 Makoto Hosono, MD PhD Kindai
FMU-ICRP Workshop on Radiological Protection in Medicine Current Status in Radionuclide Therapy Tuesday, October 3, 2017 Makoto Hosono, MD PhD Kindai University Faculty of Medicine, Osaka, Japan Current
More informationGa68 Imaging. Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium
Ga68 Imaging Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium 68 Ga Produced by a 68 Ge/ 68 Ga generator Decays by positron emission
More informationFAX, A FEMALE ADULT VOXEL PHANTOM FOR RADIATION PROTECTION DOSIMETRY
EFFECTIVE DOSE RATIOS FOR THE TOMOGRAPHIC MAX AND FAX PHANTOMS ******************************************************** EFFECTIVE DOSE RATIOS FOR TOMOGRAPHIC AND STYLIZED MODELS FROM > EXTERNAL EXPOSURE
More informationAccuracy and reproducibility of simplified QSPECT dosimetry for personalized 177 Luoctreotate
Del Prete et al. EJNMMI Physics (2018) 5:25 https://doi.org/10.1186/s40658-018-0224-9 EJNMMI Physics ORIGINAL RESEARCH Open Access Accuracy and reproducibility of simplified QSPECT dosimetry for personalized
More informationEJNMMI Physics. Pedro L. Esquinas 1,2*, Ajit Shinto 3, Koramadai K. Kamaleshwaran 3, Jephy Joseph 3 and Anna Celler 1,2
Esquinas et al. EJNMMI Physics (2018) 5:30 https://doi.org/10.1186/s40658-018-0227-6 EJNMMI Physics ORIGINAL RESEARCH Open Access Biodistribution, pharmacokinetics, and organ-level dosimetry for 188 Re-AHDD-
More informationQuantitative Imaging: A hospital physicist s perspective James Scuffham
Quantitative Imaging: A hospital physicist s perspective James Scuffham Clinical Scientist, Royal Surrey County Hospital NHS Foundation Trust Associate Tutor, University of Surrey Background The Royal
More informationSmall-cell lung cancer (SCLC) accounts for 15% to 18% of
BRIEF REPORT Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients Martina Sollini, MD,* Daniela Farioli, MS,* Armando
More informationFeasibility of simplifying renal dosimetry in
Sundlöv et al. EJNMMI Physics (2018) 5:12 https://doi.org/10.1186/s40658-018-0210-2 EJNMMI Physics ORIGINAL RESEARCH Feasibility of simplifying renal dosimetry in 177 Lu peptide receptor radionuclide therapy
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationSession 6 NEW TECHNIQUES IN RADIATION TREATMENT. Chairman : Françoise MORNEX
Session 6 NEW TECHNIQUES IN RADIATION TREATMENT Chairman : Françoise MORNEX INTERNAL IRRADIATION FOR ENDOCRINE TUMORS Emmanuel DESHAYES INTERNAL IRRADIATION FOR ENDOCRINE TUMORS Dr Emmanuel DESHAYES Nuclear
More informationUnderstanding Biological Activity to Inform Drug Development
National Cancer Policy Forum Understanding Biological Activity to Inform Drug Development December 12, 2016 Wolfgang Weber Molecular Imaging and Therapy Service Department of Radiology RECIST Response
More informationY90 SIRT Therapy Dosimetric Aspects
Y90 SIRT Therapy Dosimetric Aspects David Chee-Eng Ng MBBS, BSc, MSc, MRCP, FAMS, FRCP (Edin) Head and Senior Consultant, Department of Nuclear Medicine and PET Singapore General Hospital Adjunct Assistant
More informationTargeted Radionuclide Therapy with 90 Y-DOTATOC in Patients with Neuroendocrine Tumors
Targeted Radionuclide Therapy with 90 Y-DOTATOC in Patients with Neuroendocrine Tumors FLAVIO FORRER 1, CHRISTIAN WALDHERR 1, HELMUT R. MAECKE 2 and JAN MUELLER-BRAND 1 1 Institute of Nuclear Medicine
More informationPatient information file
Internal irradiation of neuroendocrine tumors with Yttrium-90-DOTATOC, a radiolabeled somatostatin analogue Patient information file Ladies and Gentlemen You are diagnosed with a neuroendocrine tumor and
More informationPage 1 of CONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXUMIN safely and effectively. See full prescribing information for AXUMIN. AXUMIN (fluciclovine
More informationLutetium-DOTA TATE Treatment of inoperable GEP NETs
Logo 177 Lutetium-DOTA TATE Treatment of inoperable GEP NETs Dr. Augusto Llamas-Olier. Nuclear medicine department. Dr. Maria Cristina Martínez*, Dr. Alfonso Lozano** and Dr. Augusto Llamas-Olier*. *Nuclear
More informationGosewisch et al. EJNMMI Research (2018) 8:76 https://doi.org/10.1186/s13550-018-0427-z ORIGINAL RESEARCH Open Access Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA 0,Tyr 3 ]- Octreotate
More informationDownloaded from by guest on 18 November 2018
Radiation Protection Dosimetry Vol. 105, No. 1 4, pp. 581 586 (2003) Published by Nuclear Technology Publishing 2003 Nuclear Technology Publishing ASSESSMENTS FOR HIGH DOSE RADIONUCLIDE THERAPY TREATMENT
More informationTHERANOSTICS clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms
Featured Article Page 1 of 8 THERANOSTICS clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms ieter Hörsch 1, Harshad R. Kulkarni 2, Richard P. Baum 2 1 Internal
More informationRadiation Dosimetry for CT Protocols
Radiation Dosimetry for CT Protocols This document contains radiation dosimetry information from CT scans and can be used by investigators to estimate the dosimetry information required by the JRSC or
More informationPreclinical imaging and therapy. Marion de Jong
Preclinical imaging and therapy Marion de Jong Content Introduction Preclinical Imaging Preclinical Therapy to raise awareness about problems related to translation of animal studies Radiopharmaceuticals
More informationPeptide receptor radiotherapy (PRRT) has been used with
Long-Term Retention of / m -DOTATATE in Patients Investigated by g-spectrometry and g-camera Imaging Katarina Sjögreen Gleisner 1, Gustav Brolin 1, Anna Sundlöv 2, Edita Mjekiqi 1,3, Karl Östlund 4, Jan
More informationTHERANOSTICS MOLEKULARE BILDGEBUNG MITTELS PET/CT
THERANOSTICS MOLEKULARE BILDGEBUNG MITTELS PET/CT UND RADIOREZEPTORTHERAPIE VON NET Richard P. Baum Klinik für Molekulare Radiotherapie / Zentrum für Molekulare Bildgebung (PET/CT) ENETS Center of Excellence,
More informationOptimization of a routine method for bone marrow dose estimation in
Optimization of a routine method for bone marrow dose estimation in 177 Lu-EDTMP therapy- Experience in Uruguay. Teran. M 1, Paolino.A 2, Coppe.F 2, Nuñez M 2, Hermida J C 2, Gaudiano.J 2 1 Cátedra de
More informationTargeted Radionuclide Therapy:
Targeted Radionuclide Therapy: Current status and potentials for future improvements Flavio Forrer The described research in this thesis was performed at the Department of Nuclear Medicine, University
More informationJournal of Nuclear Medicine, published on June 24, 2014 as doi: /jnumed
Journal of Nuclear Medicine, published on June 24, 2014 as doi:10.2967/jnumed.114.138834 Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
More informationDiabetes mellitus and its effects on all cause mortality after radiopeptide therapy for neuroendocrine tumors
Journal of Nuclear Medicine, published on September 15, 2016 as doi:10.2967/jnumed.116.180687 Diabetes mellitus and its effects on all cause mortality after radiopeptide therapy for neuroendocrine tumors
More informationTracking Doses in the Pediatric Population
Tracking Doses in the Pediatric Population Frederic H. Fahey DSc Boston Children s Hospital Harvard Medical School frederic.fahey@childrens.harvard.edu Disclosures Sadly, none that pay me any money! SNMMI
More informationThe PET-NET Study 2016 CNETS Grant Award
The PET-NET Study 2016 CNETS Grant Award CANM Meeting April 21, 2017 Hagen Kennecke, MD, MHA, FRCPC Medical Oncology, BC Cancer Agency Associate Professor, University of British Columbia Raja Ampat, Indonesia
More informationVoxel-level dosimetry of 177 Lu-octreotate: from phantoms to patients
UNIVERSITY OF HELSINKI REPORT SERIES IN PHYSICS HU-P-D255 Voxel-level dosimetry of 177 Lu-octreotate: from phantoms to patients Eero Hippeläinen Department of Physics Faculty of Science University of Helsinki
More informationChapter 19: Radionuclide Therapy
Chapter 19: Radionuclide Therapy Slide set of 40 slides based on the chapter authored by G. Flux and Y. Du of the publication (ISBN 978 92 0 143810 2): Nuclear Medicine Physics: A Handbook for Teachers
More informationComparison of organ doses estimations in radiology with PCXMC application based on MIRD phantoms and CALDose-X application based on voxel phantoms
Comparison of organ doses estimations in radiology with PCXMC application based on MIRD phantoms and CALDose-X application based on voxel phantoms G. Gialousis 1, Z. Pappouli 2, A. Dimitriadis 2, E. Karavassilis
More informationTherapy with radionuclides
Therapy with radionuclides Aim is to acheive interaction of radiotracer and tumor cells, with minimal iraddiation of surrounding tissue (absorbed dose only to tumor cells) Assoc. prof. V. Marković, MD,
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationRadiopharmaceuticals. Radionuclides in NM. Radionuclides NUCLEAR MEDICINE. Modes of radioactive decays DIAGNOSTIC THERAPY CHEMICAL COMPOUND
Univerzita Karlova v Praze - 1. Lékařská fakulta Radiation protection NUCLEAR MEDICINE Involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear medicine study
More informationObjective. Assessment Question. I. Theranostics II. Classic Theranostic Agent
Up and Coming Research Radiopharmaceuticals Dao Le, Pharm.D, BCNP Director, Nuclear Medicine, Radiopharmacy University of Texas MD Anderson Cancer Center Objective I. Theranostics II. Classic Theranostic
More informationPredictive power of the post-treatment scans after the initial or first two courses of [ 177 Lu]-DOTA-TATE
Chicheportiche et al. EJNMMI Physics (2018) 5:36 https://doi.org/10.1186/s40658-018-0234-7 EJNMMI Physics ORIGINAL RESEARCH Open Access Predictive power of the post-treatment scans after the initial or
More informationBone targeted radionuclide therapy. Val Lewington Royal Marsden Hospital, London
Bone targeted radionuclide therapy Val Lewington Royal Marsden Hospital, London Bone malignancy Primary bone tumours Bone malignancy Primary bone tumours - chemotherapy, surgery & external beam radiotherapy
More informationPeptide receptor radionuclide therapy with radiolabelled somatostatin analogues Bodei, Lisa
University of Groningen Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues Bodei, Lisa IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)
More informationCANM ACMN Annual Meeting April
117 Lu-DOTATATE & 68 Ga-DOTATATE A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of 177 Lu- DOTATATE Treatment, with individualized dosimetry, in Patients with 68 Ga-DOTATATE PET
More informationThe radiation absorbed doses to the tumor and normal tissues in CD1 athymic mice with
MATERIALS AND METHODS Radiation Dosimetry Estimates The radiation absorbed doses to the tumor and normal tissues in CD1 athymic mice with MDA-MB-231/H2N xenografts following injection of 111 In-DTPA-Fab-PEG
More informationThe Clinical Utility of Yttrium-90 PET after SIRT
The Clinical Utility of Yttrium-90 PET after SIRT Dr Yung Hsiang Kao Department of Nuclear Medicine Austin Health Melbourne, Australia 2 nd Asia Pacific Symposium on Liver-Directed Y-90 Microspheres Therapy
More informationMolecular Imaging of Bone Metastasis Hojjat Ahmadzadehfar
Molecular Imaging of Bone Metastasis Hojjat Ahmadzadehfar Seite 1 Bone metastases Different tumors % 80 70 68% 73% 60 50 40 40% 35% 42% 36% 30 20 10 0 5% prostate bladder renal breast thyroid lung GI urological
More information8/1/2017. Disclosures. Outline. SAM Imaging Education Course 90Y-Microsphere Therapy: Emerging Trends and Future Directions
SAM Imaging Education Course Y-Microsphere Therapy: Emerging Trends and Future Directions Matt Vanderhoek, PhD Henry Ford Health System, Detroit, MI Vanessa Gates, MS Northwestern University, Chicago,
More informationCitation for the original published paper (version of record):
http://www.diva-portal.org This is the published version of a paper published in EJNMMI Research. Citation for the original published paper (version of record): Andersson, M., Johansson, L., Eckerman,
More informationNew Horizons in radionuclide therapy. John Buscombe Royal Free Hospital
New Horizons in radionuclide therapy John Buscombe Royal Free Hospital Date for you diary Interested in Radionuclide imaging and therapy using antibodies and peptides IRIST 2008 Krakow Poland 18-21 June
More informationInternational Course on THERANOSTICS AND MOLECULAR RADIOTHERAPY
International Course on THERANOSTICS AND MOLECULAR RADIOTHERAPY A Joint Initiative of IAEA BELNUC - JULES BORDET INSTITUTE OCTOBER 2-6, 2017 Venue: Auditorium Tagnon Jules Bordet Institute Boulevard de
More informationQuantifying Y-90 PET. The Challenges Associated With the QUEST Study. Michael Tapner Research & Development Project Manager Sirtex
Quantifying Y-90 PET. The Challenges Associated With the QUEST Study Michael Tapner Research & Development Project Manager Sirtex Internal Dosimetry with 90 Y Resin Microspheres: QUEST COUNT MAP ACTIVITY
More informationNuclear Medicine and PET. D. J. McMahon rev cewood
Nuclear Medicine and PET D. J. McMahon 150504 rev cewood 2018-02-15 Key Points Nuclear Medicine and PET: Imaging: Understand how Nuc Med & PET differ from Radiography & CT by the source of radiation. Be
More informationPET in Radiation Therapy. Outline. Tumor Segmentation in PET and in Multimodality Images for Radiation Therapy. 1. Tumor segmentation in PET
Tumor Segmentation in PET and in Multimodality Images for Radiation Therapy Wei Lu, Ph.D. Department of Radiation Oncology Mallinckrodt Institute of Radiology Washington University in St. Louis Outline
More informationEstimation of absorbed dose to the kidneys in patients after treatment with 177 Lu-octreotate: comparison between methods based on planar scintigraphy
Larsson et al. EJNMMI Research 2012, 2:49 ORIGINAL RESEARCH Open Access Estimation of absorbed dose to the kidneys in patients after treatment with 177 Lu-octreotate: comparison between methods based on
More informationThe utility of peptide receptor radionuclide therapy
CONTINUING EDUCATION Dosimetry in Peptide Radionuclide Receptor Therapy: A Review* Marta Cremonesi 1, Mahila Ferrari 1, Lisa Bodei 2, Giampiero Tosi 1, and Giovanni Paganelli 2 1 Division of Medical Physics,
More informationHow to optimize diagnostic nuclear techniques?
How to optimize diagnostic nuclear techniques? Prof. Dr. Christophe Deroose Nuclear Medicine - University Hospitals Leuven (UZ Leuven) Department of Imaging & Pathology KU Leuven Leuven Cancer Institute
More informationImpact of ICRP-89 Based Models on Dose Estimates for Radiopharmaceuticals and CT Exams. Stabin MG, Kost SD, Clark JH, Pickens DR, Price RR, Carver DE
Impact of ICRP-89 Based Models on Dose Estimates for Radiopharmaceuticals and CT Exams Stabin MG, Kost SD, Clark JH, Pickens DR, Price RR, Carver DE Vanderbilt University, Nashville, TN, USA Abstract New
More information